No Data
No Data
Maccura Biotechnology (300463.SZ): Obtained product registration certificates for two new products.
Maccura Biotechnology (300463.SZ) announced on August 13th that the company has recently received the Medical Device Registration Certificate (In Vitro Diagnostic Reagents) issued by the National Medical Products Administration. The products that have obtained product registration certificates are cytomegalovirus IgM antibody detection reagent kit (direct chemiluminescence method) and herpes simplex virus type 2 IgM antibody detection test kit (direct chemiluminescence method). Cytomegalovirus IgG antibody detection reagent kit (direct chemiluminescence method), as a pathogen antibody detection test kit, is currently mainly used for auxiliary diagnosis of cytomegalovirus infection. Herpes simplex virus type 2 IgM antibody detection test.
We Think Maccura BiotechnologyLtd (SZSE:300463) Can Stay On Top Of Its Debt
Maccura Biotechnology: Half-year report for the year 2024.
Maccura Biotechnology: Summary of Half-Year Report in 2024.
Maccura Biotechnology (300463.SZ) has repurchased 0.48% of its shares in total.
Maccura Biotechnology (300463.SZ) announced that as of July 31, 2024, the company has accumulated the repurchase of 2,954,300 shares of the company through a repurchase special securities account, using centralized competitive trading. The proportion of the current total share capital of the company is 0.48%, with a fill price of 12.13 yuan/share, a highest trade of 13.23 yuan/share, a lowest trade of 10.91 yuan/share and a total payment of 35,828,060.82 yuan (excluding transaction fees). The repurchase complies with the company's share repurchase plan and relevant laws and regulations.
Maccura Biotechnology (300463.SZ) has obtained two medical instrument registration certificates.
Maccura Biotechnology (300463.SZ) announced that the company recently received approval from the National Medical Products Administration and the Sichuan Provincial Drug Administration...
No Data